NASDAQ$SYRE
Spyre Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Aeglea BioTherapeutics reported financial results for Q4 2022 and provided program updates.
Aeglea BioTherapeutics reported Q4 2022 financial results, including development fee revenues of $0.2 million and a net loss of $18.8 million. The company's cash, cash equivalents, marketable securities, and restricted cash totaled $57.3 million as of December 31, 2022, expected to fund operations into Q4 2023.
- Jeffrey Goldberg appointed president and CEO.
- Senior management team strengthened with appointments of chief medical officer and chief product officer.
- Cash, cash equivalents, marketable securities, and restricted cash totaled $57.3 million as of December 31, 2022, expected to fund operations into Q4 2023.
- Received Fast Track Designation from the FDA for Pegtarviliase in Homocystinuria.
Headline financials
Revenue & EPS history
Spyre · Revenue · Quarterly
$168K
Forward guidance
Aeglea expects its cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
17 / 39 earnings
Positive
+14.6%
Q4 2023
Best reaction
-10.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | +7.6% | +3.6% | |
| Q3 2025 | +0.5% | +4.6% | +49.4% | |
| Q1 2025 | -2.0% | -0.7% | +13.2% | |
| Q4 2024 | +7.2% | +6.0% | -2.3% | |
| Q3 2024 | +5.6% | -4.4% | -27.7% | |
| Q2 2024 | -3.0% | -6.6% | +7.4% | |
| Q1 2024 | +11.8% | +19.0% | +2.0% | |
| Q4 2023 | +14.6% | +44.3% | +45.3% | |
| Q3 2023 | -2.2% | +10.8% | +102.2% | |
| Q2 2023 | -10.3% | -12.0% | +6.7% | |
| Q1 2023 | -6.6% | -9.1% | -18.3% | |
| Q4 2022 | -0.3% | +2.0% | -26.6% | |
| Q3 2022 | -9.0% | +3.7% | -59.0% | |
| Q2 2022 | +7.7% | +5.9% | +33.3% | |
| Q1 2022 | -10.9% | -5.8% | -60.0% | |
| Q4 2021 | +0.4% | -14.6% | +14.2% | |
| Q3 2021 | -5.4% | -5.8% | -22.5% | |
| Q2 2021 | -0.6% | -3.3% | +12.1% | |
| Q1 2021 | +2.2% | +4.4% | -8.1% | |
| Q4 2020 | +1.7% | +9.7% | +5.3% | |
| Q3 2020 | +4.5% | +22.1% | +3.5% | |
| Q2 2020 | -6.7% | -4.7% | +3.2% | |
| Q1 2020 | +10.6% | -4.5% | +24.0% | |
| Q4 2019 | -8.3% | -13.2% | -40.2% | |
| Q3 2019 | -4.3% | -2.2% | -4.1% | |
| Q2 2019 | -4.1% | -3.8% | -0.5% | |
| Q1 2019 | -1.9% | -2.1% | -8.7% | |
| Q4 2018 | -0.7% | +3.1% | +8.8% | |
| Q3 2018 | +0.2% | -13.0% | -13.3% | |
| Q2 2018 | +4.8% | +1.2% | -3.4% | |
| Q1 2018 | +3.5% | +0.6% | +4.0% | |
| Q4 2017 | -1.4% | +23.7% | +20.5% | |
| Q3 2017 | -4.9% | +4.5% | +0.0% | |
| Q2 2017 | -6.3% | -7.2% | +34.8% | |
| Q1 2017 | -2.2% | -2.0% | -43.4% | |
| Q4 2016 | -4.4% | -6.9% | -8.7% | |
| Q3 2016 | -1.2% | +1.3% | -7.5% | |
| Q2 2016 | +1.1% | -1.9% | +48.2% | |
| Q1 2016 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro